Proteomic analysis of JAK2V617F induced changes identifies potential new combinatorial therapeutic approaches.
Authors
Pearson, StellaWilliamson, Andrew J K
Blance, Rognvald N
Somervaille, Tim C P
Taylor, Sam
Azadbakht, Narges
Whetton, Anthony D
Pierce, Andrew
Affiliation
Stem Cell and Leukaemia Proteomics Laboratory, Manchester Academic Health Science Centre, The University of Manchester, Wolfson Molecular Imaging Centre, Withington, Manchester, UKIssue Date
2017-05-23
Metadata
Show full item recordAbstract
In excess of 90% of patients with polycythemia vera express a mutated form of JAK2, JAK2V617F. Such aberrant proteins offer great potential for the treatment of these diseases however inhibitors to JAK2 have had limited success in the clinic in terms of curing the disease. To understand the effects of this oncogene in hematopoietic cells with the aim of improving treatment strategies we undertook a systematic evaluation of the effects of JAK2V617F expression using proteomics. The effects of JAK2V617F on over 5000 proteins and 2000 nuclear phosphopeptides sites were relatively quantified using either SILAC or eight channel iTRAQ mass spectrometry. Pathway analysis of the proteins identified as changing indicated disruption to the p53 and MYC signalling pathways. These changes were confirmed using orthogonal approaches. The insight gained from this proteomic analysis led to the formation of hypothesis driven analysis on inhibitor mediated effects on primary cells from patients with a JAK2V617F mutation. Simultaneous inhibition of MYC and up-regulation of p53 led to the preferential extinction of JAK2V617F positive CD34+ cells illustrating a potential therapeutic benefit from combined targeting of p53 and MYC.Leukemia accepted article preview online, 23 May 2017. doi:10.1038/leu.2017.143.Citation
Proteomic analysis of JAK2V617F induced changes identifies potential new combinatorial therapeutic approaches. 2017 LeukemiaJournal
LeukemiaDOI
10.1038/leu.2017.143PubMed ID
28533538Type
ArticleLanguage
enISSN
1476-5551ae974a485f413a2113503eed53cd6c53
10.1038/leu.2017.143
Scopus Count
Collections
Related articles
- After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.
- Authors: Grinfeld J, Godfrey AL
- Issue date: 2017 May
- Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.
- Authors: Berkofsky-Fessler W, Buzzai M, Kim MK, Fruchtman S, Najfeld V, Min DJ, Costa FF, Bischof JM, Soares MB, McConnell MJ, Zhang W, Levine R, Gilliland DG, Calogero R, Licht JD
- Issue date: 2010 Sep 1
- Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
- Authors: Boissinot M, Cleyrat C, Vilaine M, Jacques Y, Corre I, Hermouet S
- Issue date: 2011 Feb 24
- The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera.
- Authors: Falchi M, Varricchio L, Martelli F, Marra M, Picconi O, Tafuri A, Girelli G, Uversky VN, Migliaccio AR
- Issue date: 2017 Jun
- JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway.
- Authors: De Grandis M, Cambot M, Wautier MP, Cassinat B, Chomienne C, Colin Y, Wautier JL, Le Van Kim C, El Nemer W
- Issue date: 2013 Jan 24